Arena Pharmaceuticals, Inc. (ARNA): The Short Data You Need To See
Nowadays, there are a multitude of indicators for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traders to pay attention to, but it's smart to take note of a stock's shorts.
Arena Pharmaceuticals Inc (ARNA)
Market is closed
News
- First
- << Previous
- 91 - 100
- Next >>
What to Expect From Arena Pharmaceuticals, Inc. (ARNA)'s Launch of Belviq
After years of anticipation by doctors, patients, and investors, Belviq was finally launched last week for treatment of obesity, type 2 diabetes and overweight patients with a weight-related health problem...
Arena Pharmaceuticals, Inc. (ARNA) News: Positive Rating, Anti-Obesity Drug, Post-Launch Presentation & More
Editor's Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Orexigen Therapeutics, Inc.
Abbott Laboratories (ABT), VIVUS, Inc. (VVUS) - It's Official: Obesity Is a Disease
The decision wasn't without debate, though. In fact, the AMA's Council on Science and Public Health actually recommended against calling obesity a disease.
MannKind Corporation (MNKD), Orexigen Therapeutics, Inc. (OREX): Two Biotech Approval Outcomes That Might Affect You
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Consumer Reports Says "Exercise" Rather Than Take This Drug
The U.S. weight loss market is estimated at $61 billion, with the global weight management market expected to be $650 billion by 2015.
Onyx Pharmaceuticals, Inc. (ONXX), Arena Pharmaceuticals, Inc. (ARNA): The Top 5 Diseases Caused by Obesity
In the "Global Burden of Disease" report from the World Health Organization, which was compiled over a 20-year period from 1990 through 2010 using data from 500 researchers from 50 countries, it was determined...
Arena Pharmaceuticals, Inc. (ARNA): An Obesity Drug Stock to Fatten your Portfolio?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell after the company announced the June 11 U.S. release of its obesity drug BELVIQ -- but that's not necessarily a bad thing.
Arena Pharmaceuticals, Inc. (ARNA), Rigel Pharmaceuticals, Inc. (RIGL): This Week in Biotech
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
- First
- << Previous
- 91 - 100
- Next >>
Billionaire Hedge Funds
